Biomarkers for the early detection of acute kidney injury

Mai T Nguyen, Prasad Devarajan, Mai T Nguyen, Prasad Devarajan

Abstract

Acute kidney injury (AKI), previously referred to as acute renal failure (ARF), represents a persistent problem in clinical medicine. Despite significant improvements in therapeutics, the mortality and morbidity associated with AKI remain high. A major reason for this is the lack of early markers for AKI, akin to troponins in acute myocardial disease, and hence an unacceptable delay in initiating therapy. Fortunately, the application of innovative technologies such as functional genomics and proteomics to human and animal models of AKI has uncovered several novel genes and gene products that are emerging as biomarkers. The most promising of these are chronicled in this article. These include a plasma panel [neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C] and a urine panel [NGAL, interleukin 18 (IL-18), and kidney injury molecule 1 (KIM)-1]. As they represent sequentially expressed biomarkers, it is likely that the AKI panels will be useful for timing the initial insult and assessing the duration of AKI. Based on the differential expression of the biomarkers, it is also likely that the AKI panels will distinguish between the various types and etiologies of AKI. It will be important in future studies to validate the sensitivity and specificity of these biomarker panels in clinical samples from large cohorts and from multiple clinical situations.

Figures

Fig. 1
Fig. 1
Three hypothetical receiver-operating characteristic (ROC) curves are shown. The blue (straight) line represents a biomarker with an area under the curve (AUC) of 0.5, which indicates a result that is no better than expected by random chance. The red (middle) curve yields an AUC of about 0.75, which is generally considered a good biomarker. The green (top) curve gives an AUC of approximately 0.9, which would represent an excellent biomarker

References

    1. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430.
    1. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol. 2006;17:1503–1520.
    1. Goldstein SL. Pediatric acute kidney injury: it’s time for real progress. Pediatr Nephrol. 2006;21:891–895.
    1. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J, Collins AJ. Incidence and mortality of acute renal failure in medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol. 2006;17:1135–1142.
    1. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15:1677–1689.
    1. Herget-Rosenthal S, Marggraf G, Hüsing J, Goring F, Pietruck F, Janssen O, Phillip T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115–1122.
    1. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med. 2004;30:33–37.
    1. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH. Anaritide in acute tubule necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 1997;336:828–834.
    1. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J, McKeown W, O’Shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H, Warnock D, Summer W, Hintz R, Myers B, Haenftling K, Capra W, Pike M, Guler H-P. Multicenter clinical trial of recombinant human insulin-like growth factor 1 in patients with acute renal failure. Kidney Int. 1999;55:2423–2432.
    1. Goldstein SL, Somers MJ, Baum MA, Symons JM, Brophy PD, Blowey D, Bunchman TE, Baker C, Mottes T, McAfee N, Barnett J, Morrison G, Rogers K, Fortenberry JD. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int. 2005;67:653–658.
    1. American Society of Nephrology Renal Research Report American Society of Nephrology Renal Research Report. J Am Soc Nephrol. 2005;16:1886–1893.
    1. Zerhouni E. The NIH roadmap. Science. 2003;302:63–65.
    1. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577.
    1. Pepe MS (2003) The statistical evaluation of medical tests for classification and prediction. Oxford University Press, New York.
    1. Devarajan P, Mishra J, Supavekin S, Patterson LT, Potter SS. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab. 2003;80:365–376.
    1. Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care. 2004;10:476–482.
    1. Zhou H, Hewitt SM, Yuen PST, Star RA. Acute kidney injury biomarkers-needs, present status, and future promise. Neph SAP. 2006;5(2):63–71.
    1. Nguyen M, Ross G, Dent C, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol. 2005;25:318–326.
    1. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics. 2006;5:1760–1771.
    1. Perco P, Pleban C, Kainz A, Lukas A, Mayer G, Mayer B, Oberbauer R. Protein biomarkers associated with acute renal failure and chronic kidney disease. Eur J Clin Invest. 2006;36:753–763.
    1. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta. 2000;482:298–307.
    1. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P. Differential gene expression following early renal ischemia-reperfusion. Kidney Int. 2003;63:1714–1724.
    1. Mishra J, Ma Q, Prada A, Zahedi K, Yang Y, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel urinary biomarker for ischemic injury. J Am Soc Nephrol. 2003;4:2534–2543.
    1. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil Gelatinase-Associated Lipocalin (NGAL): a novel urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–315.
    1. Mori K, Lee HT, Rapoport D, Drexler I, Foster K, Yang J, Schmidt-Ott, Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T, Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115:610–621.
    1. Schmitt-Ott KM, Mori K, Kalandadze A, Li J-Y, Paragas N, Nicholas T, Devarajan P, Barasch J. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens. 2005;15:442–449.
    1. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury following cardiac surgery. Lancet. 2005;365:1231–1238.
    1. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006;105:485–491.
    1. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, Devarajan P. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol. 2006;21:856–863.
    1. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelstein CL, Devarajan P. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6:1639–1645.
    1. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P. Urinary neutrophil gelatinase-associated lipocalin in D+HUS: a novel marker of renal injury. Pediatr Nephrol. 2006;21:989–994.
    1. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006;26:287–292.
    1. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol Dial Transplant. 2007;22:295–296.
    1. Devarajan P, Hirsch R, Dent C, Pfriem H, Allen J, Beekman R, Mishra J, Ma Q, Kelly C, Mitsnefes M. NGAL is an early predictive biomarker of acute kidney injury following contrast administration. J Am Soc Nephrol. 2006;17:48A.
    1. Zappitelli M, Washburn K, Arikan AA, Mishra J, Loftis L, Devarajan P, Goldstein SL. Urine NGAL is an early predictive biomarker of acute kidney injury in critically ill children. J Am Soc Nephrol. 2006;17:404A.
    1. Mitsnefes M, Kathman T, Mishra J, Kartal J, Khoury P, Nickolas T, Barasch J, Devarajan P. Serum NGAL as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007;22:101–108.
    1. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–226.
    1. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Phillip T, Kribben A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem. 2004;50:552–558.
    1. VandeVoorde RG, Katlman TI, Ma Q, Kelly C, Mishra J, Dent CA, Mitsnefes MM, Devarajan P. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury. J Am Soc Nephrol. 2006;17:404A.
    1. Han WK, Bailly V, Abichandani R, Thadani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237–244.
    1. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286:F552–F563.
    1. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2006;290:F517–F529.
    1. Liangos O, Han WK, Wald R, Perianayagam MC, Mackinnon RW, Dolan N, Warner KG, Symes JF, Bonventre JV, Jaber BL. Urinary kidney injury molecule-1 level is an early and sensitive marker of acute kidney injury following cardiopulmonary bypass. J Am Soc Nephrol. 2006;17:403A.
    1. Han WK, Waikar SS, Johnson A, Curhan GC, Devarajan P, Bonventre JV. Urinary biomarkers for early detection of acute kidney injury. J Am Soc Nephrol. 2006;17:403A.
    1. Melnikov VY, Ecder T, Fantuzzi G, Siegmund B, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL. Impaired IL-18 processing protects caspase-1 deficient mice from ischemic acute renal failure. J Clin Invest. 2001;107:1145–1152.
    1. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43:405–414.
    1. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046–3052.
    1. Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, Devarajan P, Edelstein CL. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70:199–203.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere